Of course, we should not block something which is usable for others.Ĭraig: One of the other differences between your vaccine and the others is the cold storage requirement. So we need to develop this further as the others need as well. Ingmar Hoerr and Florian von der Mulbe were starting this company 20 years ago, on this basis of the technology others are developing vaccines which is good – also you see that the efficacy of the other vaccines is is going down because of the variants. And again, I think we hit the goal but not as good as others. Haas: Well in the fields of innovation, if you give up, just … you didn’t hit your goal in the first place. What is your response to that to those kinds of arguments that you should just give up? Maybe you should just make somebody else’s vaccine. And if you then compare the share price to others and say the potential of the entire platform is there, we are just starting, I say, OK, do you want to be early or late?Ĭraig: There was a an interesting perspective that somebody published a month or two ago that argued you haven’t been able to have the efficacy that you want from the vaccine, because you have access to the supply chain to develop these kinds of vaccines that are already on the market. And of course, if you don’t have good news to report, it will have an impact on your share price. And the public listing brings you to explain. And then the multivalent and the next one.
#How to watch pretty cure full
Yes, we have not been the first one, but we have high hopes that the data are good enough for approval, then we have to take a decision when is that we say now we’ll shift over to the second generation to be full speed. Do you worry how that could affect your ability to continue developing? But if you publish disappointing results, you can see a negative stock price reaction. You know there are pros and cons to being a public company. (Credit: Thomas Kienzle/AFP via Getty Images)Ĭraig: Your company recently went public in the U.S. Victoria Craig: Do you worry that your vaccine won’t reach the required efficacy for approval?Ĭurevac’s boss told the BBC he’s not giving up on delivering an effective COVID-19 vaccine. You need a lot of expertise of people who have been doing it.”īelow is a transcript of Victoria Craig’s conversation with Franz-Werner Haas. “We have never – and all the other mRNA companies also have never – been doing these kinds of phase three trials globally. “You know, when we started this entire endeavor, we have been 450 people, now we have 750 people to organize a clinical trial, which at the end of the day also included 40,000 subjects globally in a time where you are not allowed to travel,” Haas said. Haas explains, though, that he’s determined to keep going, and the more than $170 million partnership with GlaxoSmithKline announced in February has been a game changer. In June, CureVac said its vaccine was 47% effective in a late stage trial, and this month, it cancelled two manufacturing deals after other drugmakers boosted their own production. This company is still trying to boost its candidate’s efficacy. The road to developing a COVID-19 vaccine has been a long one for CureVac, as its rivals continue to ship billions of doses to countries around the world. The BBC’s Victoria Craig sat down with the company’s CEO, Franz-Werner Haas, at the company’s Tubingen headquarters, where he said he’s not giving up and he believes a partnership with GlaxoSmithKline is helping. CureVac was the first to use messenger RNA technology in medicine, and that’s now been deployed in the Pfizer-BioNTech and Moderna COVID-19 vaccines.īut CureVac’s first-generation vaccine fell well short of the efficacy rates achieved by its competitors, and it hasn’t yet been able to put one on the market. When the race to develop a COVID-19 vaccine began last year, a 20-year-old company in southwestern Germany was thought to be uniquely positioned to deliver one.
0 kommentar(er)
